Ironwood Pharmaceuticals | IRWD - Assets


Ironwood Pharmaceuticals reported $290.59M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Akebia Therapeutics USD 342.13M 7.53M Sep/2026
Almirall EUR 2.37B 29.97M Jun/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amarin USD 634.08M 9.72M Sep/2026
Ardelyx USD 587.52M 11.63M Sep/2026
Astellas Pharma JPY 3.53T 164.74B Sep/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Charles River Laboratories USD 7.45B 80.64M Sep/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Ironwood Pharmaceuticals USD 290.59M 5.46M Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
MacroGenics USD 318.68M 26.72M Sep/2026
Moderna USD 13.47B 2.51B Sep/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
Pacira USD 34.68B 33.44B Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Takeda JPY 15.27T 391.77B Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025